Our top pick for
Athenex, Inc is a drug manufacturers—specialty & generic business based in the US. Athenex shares (ATNX) are listed on the NASDAQ and all prices are listed in US Dollars. Athenex employs 574 staff and has a trailing 12-month revenue of around USD$140.8 million.
Since the stock market crash in March caused by coronavirus, Athenex's share price has had significant negative movement.
Its last market close was USD$13.05, which is 6.72% down on its pre-crash value of USD$13.99 and 131.79% up on the lowest point reached during the March crash when the shares fell as low as USD$5.63.
If you had bought USD$1,000 worth of Athenex shares at the start of February 2020, those shares would have been worth USD$486.63 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$942.21.
|Latest market close||USD$13.05|
|52-week range||USD$5.63 - USD$18.35|
|50-day moving average||USD$12.6054|
|200-day moving average||USD$11.4558|
|Wall St. target price||USD$28.24|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.055|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||-6.79%|
|1 month (2020-10-30)||14.47%|
|3 months (2020-08-28)||21.85%|
|6 months (2020-05-29)||20.06%|
|1 year (2019-11-29)||-16.24%|
|2 years (2018-11-30)||-1.29%|
|3 years (2017-11-30)||-23.73%|
|5 years (2015-11-27)||N/A|
|Revenue TTM||USD$140.8 million|
|Gross profit TTM||USD$-49,362,000|
|Return on assets TTM||-20.67%|
|Return on equity TTM||-80.4%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 9.7 million Athenex shares held short by investors – that's known as Athenex's "short interest". This figure is 7.7% up from 9.0 million last month.
There are a few different ways that this level of interest in shorting Athenex shares can be evaluated.
Athenex's "short interest ratio" (SIR) is the quantity of Athenex shares currently shorted divided by the average quantity of Athenex shares traded daily (recently around 1.5 million). Athenex's SIR currently stands at 6.32. In other words for every 100,000 Athenex shares traded daily on the market, roughly 6320 shares are currently held short.
However Athenex's short interest can also be evaluated against the total number of Athenex shares, or, against the total number of tradable Athenex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Athenex's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Athenex shares in existence, roughly 110 shares are currently held short) or 0.1361% of the tradable shares (for every 100,000 tradable Athenex shares, roughly 136 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Athenex.
Find out more about how you can short Athenex stock.
We're not expecting Athenex to pay a dividend over the next 12 months.
Over the last 12 months, Athenex's shares have ranged in value from as little as $5.63 up to $18.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athenex's is 0.856. This would suggest that Athenex's shares are less volatile than average (for this exchange).
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.